UCB announced today that it has licensed US marketing rights to six pharmaceutical products to Actient Pharmaceuticals, LLC, a specialty pharmaceutical company based in Deerfield, IL (US), with an option for Actient to purchase those products. Actient is a portfolio company of GTCR, a leading private equity firm based in Chicago, IL.
In 2009, the six products achieved gross annual sales of approximately USD 53 million. Under the terms of the agreement, UCB will receive an upfront payment upon closing as well as future royalty payments. Other details of the transaction have not been disclosed. This transaction is part of UCB’s long-term strategy to become the patient-centric global biopharmaceutical leader focused on immunology and neurology.
“Following the successful U.S. launches of our core products Cimzia® (certolizumab pegol) and Vimpat® (lacosamide), we continue to focus our resources on providing solutions to patients who suffer from severe diseases in immunology and neurology,” said Greg Duncan, UCB’s President for North American Operations. “This transaction enables us to increase both financial and human resources to support continued growth of Cimzia® and Vimpat®.”
Products in the transaction include: Edex® (alprostadil for injection), Theo-24® (theophylline anhydrous), Semprex®-D Capsules (acrivastine and pseudoephedrine hydrochloride), Levatol® (penbutolol sulfate), Robaxin® (methocarbamol tablets, USP) and Dilatrate®-SR (isosorbide dinitrate). The product set will form the basis of a commercial platform upon which Actient will continue to license and acquire strategic pharmaceutical assets.